Role of advanced glycation end products as new biomarkers in systemic lupus erythematosus

Carrión-Barberà, María Irene; Triginer, Laura; Tío, Laura; Pérez-García, Carolina; Ribes, Anna; Abad, Victoria; Pros Simón, Ana; Bermúdez-López, Marcelino; Castro-Boqué, Eva; Lecube, Albert; Valdivielso, Jose Manuel; Ilervas Project Group; Monfort, Jordi; Salman-Monte, Tarek Carlos

doi:http://dx.doi.org/10.3390/ijms25053022

Role of advanced glycation end products as new biomarkers in systemic lupus erythematosus

License

Citation

Carrión-Barberà I, Triginer L, Tío L, Pérez-García C, Ribes A, Abad V, et al. Role of advanced glycation end products as new biomarkers in systemic lupus erythematosus. Int J Mol Sci. 2024 Mar 5;25(5):3022. DOI: 10.3390/ijms25053022

Abstract

Advanced glycation end-products (AGEs) may play a relevant role as inducers in the chronic inflammatory pathway present in immune-mediated diseases, such as systemic lupus erythematosus (SLE). AGEs concentrations have been associated, with discrepant results to date, with some parameters such as disease activity or accrual damage, suggesting their potential usefulness as biomarkers of the disease. Our objectives are to confirm differences in AGEs levels measured by cutaneous autofluorescence between SLE patients and healthy controls (HC) and to study their correlation with various disease parameters. Cross-sectional study, where AGEs levels were measured by skin autofluorescence, and SLE patients' data were compared with those of sex- and age-matched HC in a 1:3 proportion through a multiple linear regression model. Associations of AGEs levels with demographic and clinical data were analyzed through ANOVA tests. Both analyses were adjusted for confounders. AGEs levels in SLE patients were significantly higher than in HC (p < 0.001). We found statistically significant positive associations with SLE disease activity index (SLEDAI) and damage index (SDI), physician and patient global assessment, C-reactive protein, leukocyturia, complement C4, IL-6 and oral ulcers. We also found a negative statistically significant association with current positivity of anti-nuclear and anti-Ro60 antibodies. AGEs seem to have a contribution in LES pathophysiology, being associated with activity and damage and having a role as a new management and prognosis biomarker in this disease. The association with specific antibodies and disease manifestations may indicate a specific clinical phenotype related to higher or lower AGEs levels.